在接受米罗加巴林与普雷加巴林的老年患者中,包括骨折在内的不良事件:使用日本大型索赔数据库进行的回顾性队列研究
Kanako Makito1, Akira Okada2, Hideo Yasunaga3
1Department of Biostatistics, School of Public Health, The University of Tokyo, Japan.
Annals of clinical epidemiology
|April 14, 2025
概括
与普雷加巴林相比,米罗加巴林可能会略微减少老年人骨折等不良事件,尽管临床意义最小. 需要进一步的研究来证实这些发现用于神经病痛治疗.
科学领域:
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 米洛加巴林和普雷加巴林用于神经病痛.
- 严重的副作用,如老年患者的跌倒相关骨折,需要进行比较.
- 这项研究评估了米罗加巴林与普雷加巴林对老年人不良事件的评估.
研究的目的:
- 为了在65岁及以上的患者中比较米罗加巴林和普雷加巴林的不良事件,特别是与跌倒相关的骨折.
- 为了确定米罗加巴林是否在这个人口群体中比普雷加巴林提供了安全优势.
主要方法:
- 使用日本DeSC数据库进行的回顾性队列研究 (2019年4月-2021年5月).
- 包括130,244名65岁以上的患者接受了米罗加巴林或普雷加巴林治疗.
- 主要结局:骨折或药物切换;使用卡普兰-梅尔和考克斯模型进行分析. 敏感性分析排除了接受其他止痛药的患者.
主要成果:
- 在平均2.8个月的随访期间,分析了米罗加巴林 (29,686) 和普雷加巴林 (100,558) 组.
- 结果率为米罗加巴林的50.1/100人/年,而前加巴林的42.8/100人/年.
- 米洛加巴林显示出较低风险的非显著趋势 (HR 0.93; 95% CI 0.87-1.00);灵敏度分析显示没有差异 (HR 0.93; 95% CI 0.86-1.01).
结论:
- 米罗加巴林可能与研究的不良结果的发病率略低相关.
- 观察到的米罗加巴林和普雷加巴林之间的差异没有临床意义.
- 需要进一步的研究来验证这些发现并确认临床相关性.
更多相关视频
03:07Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)
Published on: July 12, 2024
791
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
138
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...